Weight loss drug Ozempic cuts depression, anxiety, and addiction risk
Why it matters: Ozempic and similar drugs could revolutionize mental health treatment, offering a dual benefit for metabolic and psychiatric conditions.
- GLP-1 medications, including semaglutide (Ozempic, Wegovy, Rybelsus), are linked to a 42% reduction in psychiatric-related hospital visits and sickness absence.
- Semaglutide users experienced a 44% lower risk of depression and a 38% reduction in anxiety disorders during treatment periods.
- The study also found a 47% decrease in substance use disorders and a reduced risk of suicidal behavior among those taking GLP-1 receptor agonists.
- Researchers suspect both lifestyle improvements from weight loss and direct effects of the drugs on the brain contribute to these mental health benefits, with Professor Mark Taylor noting earlier studies hinted at reduced alcohol use disorder.
New research from the University of Eastern Finland, Karolinska Institutet, and Griffith University suggests GLP-1 medications like Ozempic may significantly reduce the risk of depression, anxiety, and substance use disorders, alongside their known weight loss benefits. This large-scale study observed substantial drops in psychiatric-related hospital visits and mental health issues among users, pointing to potential direct brain effects and lifestyle improvements.
